Carmine N. Stengone - Jan 31, 2025 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role
CEO and President, Director
Signature
/s/ Peter Slover, Attorney-in-Fact
Stock symbol
CTNM
Transactions as of
Jan 31, 2025
Transactions value $
$0
Form type
4
Date filed
1/31/2025, 04:35 PM
Previous filing
Sep 12, 2024
Next filing
Apr 2, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTNM Stock Option (right to buy) Award $0 +300K $0.00 300K Jan 31, 2025 Class A Common Stock 300K $9.79 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service.